IDXX Idexx Laboratories
$560.42
▲ 2.4%Updated Oct 16, 2:25 PM ET
Report Card
IDXX at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Favorable · 65/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 8.1% in the year to Jul 6, 2026
Key Metrics
Market Cap
$44.00B
P/E
40.4x
Forward P/E (est.)
32.17x
ROE
70.9%
Revenue Growth
13.1%
EPS Growth
25.6%
Profit Margin
24.6%
FCF Yield
1.9%
Debt / Equity
0.53x
ROIC
52.0%
Interest Coverage
32.71x
Current Ratio
1.17x
Dividend Yield
—
Implied Growth (rev. DCF)
6.4%
Rating Score
65/100
Business Overview
Idexx Laboratories (IDXX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $44.00B.
In its latest reported year it generated about $4.30B in revenue and $1.06B in net profit.
Our model rates IDXX Favorable (65/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedThe filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
60.9% average over the last 3 years
±2.2 pts around 58.2% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 9 of 9 years
52.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what IDXX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. IDXX trades near $560.42, around its 50-day average ($555.90) and 200-day average ($628.05). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 50 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. IDXX's is $17.47 (~3.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, IDXX found buyers near $518.55 (support) and sellers near $581.47 (resistance); its 52-week range then was $506.91–$769.98. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.2× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
7.6%
Revenue moved from $1.78B in 2016 to $4.30B in 2025, a 10.3% compound annual growth rate. The most recent year grew a steady 13.1% year over year. Consistent top-line growth is one sign of healthy demand.
Profitability
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
ROE
70.9%
Idexx Laboratories keeps about 24.6% of each sales dollar as net profit, with a 61.8% gross margin and 31.6% operating margin. Return on equity is 70.9% and return on invested capital about 52.0%. Margins this wide usually signal pricing power or a cost advantage.
Debt Analysis
Total Debt
$450.00M
Net Debt
$253.07M
Net Debt / EBITDA
0.19x
Debt / Equity
0.53x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 32.7x, with a current ratio of 1.2x. That is a moderate, manageable debt load for most businesses. It carries roughly $450.00M of total debt against $196.93M of cash.
Cash Flow Analysis
Operating CF
$1.18B
Free Cash Flow
$1.06B
FCF Margin
24.6%
In the latest year Idexx Laboratories produced about $1.18B of operating cash flow and $1.06B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
40.4x
P/S
10.51x
P/B
32.91x
EV / EBITDA
—
IDXX trades at 40.4x trailing earnings (about 32.2x on estimated forward earnings), 10.5x sales, and 32.9x book value. Reverse-engineering today's price implies the market expects roughly 6.4% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$382.22
Current price
$560.42
Starting FCF (latest 10-K)
$1.06B
Growth, years 1–5
13.1%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where IDXX sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How IDXX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, IDXX ranks #17 by our overall rating. It trades at a premium versus the sector on earnings (40.4x P/E vs. 26.1x median) with a higher return on equity (70.9% vs. 14.1%) and faster revenue growth (13.1% vs. 7.6%).
P/E vs sector
40.4x
median 26.1x
ROE vs sector
70.9%
median 14.1%
Growth vs sector
13.1%
median 7.6%
Sector rank
#17
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$605.95 – $1,009.92
vs. $560.42 today · implied CAGR 2% – 13%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.86B | $5.50B | $6.21B | $7.02B | $7.93B |
| Net income | $1.22B | $1.37B | $1.55B | $1.75B | $1.98B |
| EPS | $15.49 | $17.50 | $19.77 | $22.34 | $25.25 |
| Share price (low) | $371.64 | $419.95 | $474.55 | $536.24 | $605.95 |
| Share price (high) | $619.40 | $699.92 | $790.91 | $893.73 | $1,009.92 |
| CAGR (low–high) | -34% / 11% | -13% / 12% | -5% / 12% | -1% / 12% | 2% / 13% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for IDXX:
- Revenue is growing 13.1% a year, a sign of real demand.
- High net margins (24.6%) point to pricing power or efficiency.
- Strong return on equity (70.9%) shows capital is put to work well.
- Our model's overall read is Favorable (65/100).
Bear Case
The case against IDXX:
- A rich 40.4x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Valuation risk — at 40.4x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen favourably: Idexx Laboratories is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 40.4x earnings, which our model scores Favorable (65/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 22 Wall Street analysts covering IDXX recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
IDXX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
IDXX — frequently asked questions
Is IDXX a good stock to buy?
We don't give buy or sell advice. Our model rates Idexx Laboratories Favorable (65/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is IDXX's rating on The Stocks School?
Idexx Laboratories currently scores 65/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does IDXX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Idexx Laboratories's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for IDXX calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this IDXX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell IDXX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.